Thus, our findings extend those of the previous study that demonstrated the efficacy of febuxostat in NASH mice, by revealing the pathophysiological impact of hepatic UA levels and XO activity rather than plasma UA levels on the development of NAFLD. Here, XDH is linked to metabolic dysfunction-associated steatohepatitis.